Histone deacetylase inhibitors for enhancing activity of antifungal agent: a patent evaluation of WO2014041424(A1).
Novel histone deacetylase inhibitors have been developed for the antifungal therapy. Molecule 8 exhibited potent antifungal activities with MIC values of 0.25/0.25, 0.12/0.25, 0.12/0.12 µg/ml against Candida albicans, C. parapsilosis and C. glabrata after 24/48 h incubation, respectively. Most of the synthesized compound showed significantly synergistic effects with fluconazole in the biological assay. The discovery of these molecules makes positive contributions to the development of potent and safe antifungal drugs.
Qingdao University , Qingdao , China.
Lei
L
Zhang
Wenfang
W
Xu
D000935:Antifungal Agents / Q000008:administration & dosage / Q000494:pharmacology*; D002175:Candida / Q000187:drug effects*; D002176:Candida albicans / Q000187:drug effects; D041221:Candida glabrata / Q000187:drug effects; D015195:Drug Design; D004357:Drug Synergism; D015725:Fluconazole / Q000008:administration & dosage / Q000494:pharmacology; D056572:Histone Deacetylase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D008826:Microbial Sensitivity Tests; D010330:Patents as Topic
D000935:Antifungal Agents; D056572:Histone Deacetylase Inhibitors; D015725:Fluconazole
antifungal; histone deacetylase; inhibitor; selectivity